SiranBio Enters $1.005B Global Licensing Deal with GSK for First-in-Class ALK7-Targeting siRNA Drug SA030

5Month6Day, SiranBio announced its collaboration with GlaxoSmithKline (GSK) RegardingSA030Reach an exclusive global licensing agreement (excluding mainland China, Hong Kong, Macao, and Taiwan).SA030Is a potential first-in-class, long-acting small interferingRNA（siRNA) Oligonucleotides, currently in the development stage, are intended for the treatment of metabolic and cardiovascular diseases.SA030Recently, it has entered I Phase Clinical Trial, Targeting Activin Receptor-Like Kinase7（ALK7）—— This is an established therapeutic mechanism for cardiometabolic diseases.

According to the agreement, GlaxoSmithKline (GSK) will pay the upfront payment, as well as future milestone payments based on the successful achievement of development, registration, and commercialization, with a total amount up to 10.05 USD billion; meanwhile, a tiered royalty will be paid based on global net product sales (excluding mainland China, Hong Kong, Macao, and Taiwan).

SiranBio (SiranBio) will dominateSA030Clinical development work until I Upon completion of the Phase III clinical trial, GSK will assume responsibilities for development, regulatory submissions, and commercialization outside of mainland China, Hong Kong, Macau, and Taiwan.

Cardiometabolic diseases are approximately50%The Primary Cause of Death in Patients with Chronic Kidney Disease and Liver Disease. Targeted ALK7Can reduce abdominal fat (visceral adipose tissue) while preserving lean body mass,VAT), thereby improving insulin sensitivity, lipid profile, and reducing adipocyte-driven inflammation. Increasing evidence suggests that visceral adipose tissue (VAT) is associated with cardiometabolic risk; in patients with chronic inflammatory diseases, reducing this indicator has a greater impact on patient survival than managing only the underlying disease.

Preclinical studies have shown,SA030Characterized by differentiated long-acting properties, it can intervene in fundamental inflammation associated with cardiometabolic risks through adipocyte-targeted delivery and a low-frequency dosing regimen.SA030With GLP-1Agonist,SGLT2Inhibitors with complementary and unique mechanisms provide support for potential future combination therapy regimens to reduce residual cardiometabolic risks that existing therapies have not fully addressed.

Suzhou Siran Biotechnology Co.,Ltd.2022Year5Founded in Suzhou Industrial Park in the month of [specific month], it is a company focused on innovation.siRNAA biotechnology enterprise focused on drug research and development. The company has established a platform technology system with independent intellectual property rights, coveringsiRNAThe Entire Process of Drug Development.SiranBio SA1211Is the world's first dual-target to enter the clinical trial stagesiRNADrug.The company is insiRNASiranBio has a globally leading level in the field of fat-targeted delivery and extrahepatic delivery technology. Currently, the company has built a nucleic acid drug R&D pipeline covering antiviral, cardiovascular, and metabolic disease fields, and has launched multiple out-licensing and strategic cooperation projects with top pharmaceutical enterprises and biotechnology companies both in China and internationally.

Dr. Zhiwei Yang, founder and CEO of SiranBio, stated:“SiranBio has the world's leading small nucleic acid extrahepatic delivery technology and R&D pipeline. GlaxoSmithKline (GSK) The resource advantages and clinical development capabilities will greatly accelerate SiranBio's innovative R&D pipeline towards therapeutic drug conversion, benefiting more people in the fields of fat reduction and fat-related chronic diseases.”